August 18, 2025 — Leads & Copy — Diamond Equity Research has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA) following quarterly results. The update note includes detailed information on the MAIA Biotechnology’s business, recent updates, management commentary, financial results, valuation, and risks.
MAIA Biotechnology advanced its lead telomere-targeting candidate, ateganosine (THIO), across clinical, regulatory, and pipeline fronts during the quarter, strengthening clinical momentum in Q2 2025 with Phase 2 NSCLC survival data, Fast Track Designation, and global trial progress. Updated results from the pivotal Phase 2 THIO-101 study in advanced NSCLC reported a median overall survival of 17.8 months in the intent-to-treat set of 22 third-line patients. Treatment remained generally well tolerated. The trial expanded into Asia with first dosing in Taiwan and ongoing screening in Europe and Asia. The company also entered into a master clinical supply agreement with Roche to evaluate ateganosine in sequence with atezolizumab (Tecentriq®) across multiple hard-to-treat cancers and strengthened clinical guidance by appointing two hepatocellular carcinoma specialists to its Scientific Advisory Board. The FDA granted Fast Track designation for the treatment of non-small cell lung cancer (NSCLC). Beyond NSCLC, the company plans to initiate studies in breast, prostate, gastric, pancreatic, and ovarian cancers.
Diamond Equity Research has revised its valuation model to incorporate the most recent financial results, updated share count, and re-evaluated the comparable company analysis, yielding a valuation of $10.27 per share contingent on successful execution by the company.
Founded in 2018 and headquartered in Chicago, Illinois, MAIA is a biotechnology company engaged in discovering, developing, and commercializing novel cancer therapies with high unmet medical needs.
Contact: Diamond Equity Research, research@diamondequityresearch.com
Source: Diamond Equity Research
